Please note that this product was withdrawn from the Union Register of orphan medicinal products in May 2021 on request of the Sponsor.
On 4 July 2014, orphan designation (EU/3/14/1289) was granted by the European Commission to A1M Pharma AB, Sweden, for recombinant human alpha-1-microglobulin for the treatment of pre‑eclampsia.
In April 2021, A1M Pharma AB changed name to Guard Therapeutics International AB.
Recombinant human alpha-1-microglobulin
Treatment of pre-eclampsia
|Date of designation||
|Orphan designation status||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.